Literature DB >> 10559314

Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication.

L Berthoux1, C Péchoux, J L Darlix.   

Abstract

Human immunodeficiency virus type 1 nucleocapsid protein is a major structural component of the virion core and a key factor involved in proviral DNA synthesis and virus formation. 2,2'-Dithiobenzamides (DIBA-1) and related compounds that are inhibitors of NCp7 are thought to eject zinc ions from NCp7 zinc fingers, inhibiting the maturation of virion proteins. Here, we show that the presence of DIBA-1 at the time of virus formation causes morphological malformations of the virus and reduces proviral DNA synthesis. Thus, it seems that DIBA-1 is responsible for a "core-freezing effect," as shown by electron microscopy analyses. DIBA-1 can also directly interfere with the fate of the newly made proviral DNA in a manner independent of its effects on virion core formation. These data strongly suggest that nucleocapsid protein is a prime target for new compounds aimed at inhibiting human immunodeficiency virus and other retroviruses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10559314      PMCID: PMC113051     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  ADA, a potential anti-HIV drug.

Authors:  M Vandevelde; M Witvrouw; J C Schmit; S Sprecher; E De Clercq; J P Tassignon
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

2.  Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  D Lamarre; G Croteau; E Wardrop; L Bourgon; D Thibeault; C Clouette; M Vaillancourt; E Cohen; C Pargellis; C Yoakim; P C Anderson
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Viral resistance and the selection of antiretroviral combinations.

Authors:  B A Larder
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995

4.  Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein.

Authors:  W G Rice; J A Turpin; M Huang; D Clanton; R W Buckheit; D G Covell; A Wallqvist; N B McDonnell; R N DeGuzman; M F Summers; L Zalkow; J P Bader; R D Haugwitz; E A Sausville
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

5.  Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins.

Authors:  W G Rice; D C Baker; C A Schaeffer; L Graham; M Bu; S Terpening; D Clanton; R Schultz; J P Bader; R W Buckheit; L Field; P K Singh; J A Turpin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Authors:  Y M Zhang; H Imamichi; T Imamichi; H C Lane; J Falloon; M B Vasudevachari; N P Salzman
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

7.  Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis.

Authors:  L Berthoux; C Péchoux; M Ottmann; G Morel; J L Darlix
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Effects of nucleocapsid mutations on human immunodeficiency virus assembly and RNA encapsidation.

Authors:  Y Zhang; E Barklis
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  A new reporter cell line to monitor HIV infection and drug susceptibility in vitro.

Authors:  A Gervaix; D West; L M Leoni; D D Richman; F Wong-Staal; J Corbeil
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

10.  Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity.

Authors:  D T Poon; J Wu; A Aldovini
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

View more
  12 in total

1.  Reversal by dithiothreitol treatment of the block in murine leukemia virus maturation induced by disulfide cross-linking.

Authors:  Stephen Campbell; Masamichi Oshima; Jane Mirro; Kunio Nagashima; Alan Rein
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  The role of lysine 186 in HIV-1 integrase multimerization.

Authors:  Lionel Berthoux; Sarah Sebastian; Mark A Muesing; Jeremy Luban
Journal:  Virology       Date:  2007-03-29       Impact factor: 3.616

Review 3.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

4.  Quantitative interferometric reflectance imaging for the detection and measurement of biological nanoparticles.

Authors:  Derin Sevenler; Oğuzhan Avci; M Selim Ünlü
Journal:  Biomed Opt Express       Date:  2017-05-17       Impact factor: 3.732

5.  Effects of the nature and concentration of salt on the interaction of the HIV-1 nucleocapsid protein with SL3 RNA.

Authors:  Shreyas S Athavale; Wei Ouyang; Mark P McPike; Bruce S Hudson; Philip N Borer
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

6.  Alteration of zinc-binding residues of simian immunodeficiency virus p8(NC) results in subtle differences in gag processing and virion maturation associated with degradative loss of mutant NC.

Authors:  J L Yovandich; E N Chertova; B P Kane; T D Gagliardi; J W Bess; R C Sowder; L E Henderson; R J Gorelick
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

7.  HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.

Authors:  Joshua N Leonard; Priya S Shah; John C Burnett; David V Schaffer
Journal:  Cell Host Microbe       Date:  2008-11-13       Impact factor: 21.023

8.  A cooperative and specific DNA-binding mode of HIV-1 integrase depends on the nature of the metallic cofactor and involves the zinc-containing N-terminal domain.

Authors:  Kevin Carayon; Hervé Leh; Etienne Henry; Françoise Simon; Jean-François Mouscadet; Eric Deprez
Journal:  Nucleic Acids Res       Date:  2010-02-17       Impact factor: 16.971

9.  Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA.

Authors:  Lionel Berthoux; Sarah Sebastian; Elena Sokolskaja; Jeremy Luban
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 nucleocapsid inhibitors impede trans infection in cellular and explant models and protect nonhuman primates from infection.

Authors:  Gregory S Wallace; Cecilia Cheng-Mayer; Marco L Schito; Patricia Fletcher; Lisa M Miller Jenkins; Ryo Hayashi; A Robert Neurath; Ettore Appella; Robin J Shattock
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.